Roadmap for the establishment of a European vaccine R&D infrastructure
| Autor: | Stefan Jungbluth, Nathalie Imbault, Mark J. Geels, Joanna Korejwo, Odile Leroy, Betty Dodet |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Vaccine research
Biomedical Research Services Public administration Capital Financing Political science Immunology and Microbiology(all) Drug Discovery media_common.cataloged_instance Animals Humans Technology Pharmaceutical European commission European Union European union media_common Vaccines General Veterinary General Immunology and Microbiology R&D business.industry Member states Environmental resource management Public Health Environmental and Occupational Health Research infrastructure Private sector veterinary(all) 3. Good health Europe Infectious Diseases Molecular Medicine business Stakeholder consultation |
| Zdroj: | Vaccine. 32(51):7021-7024 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2014.08.014 |
| Popis: | To consolidate the integration of the fragmented European vaccine development landscape, TRANSVAC – the European Network of Vaccine Research and Development, funded by the European Commission (EC) – has initiated the development of a roadmap through a process of stakeholder consultation. The outcome of this consultation highlighted the need for transnational cooperation and the opportunities that could be generated by such efforts. This cooperation can be achieved through the establishment of a European Vaccine Research and Development Infrastructure (EVRI). EVRI will support cooperation between existing vaccine Research and Development (R&D) organisations from the public and private sector and other networks throughout Europe. It will become sustainable over time by receiving support from multiple sources including the EC, European Union (EU) Member States, European vaccine companies, EVRI partner organisations, and by income generated. Different stakeholders have demonstrated support for the concept of a vaccine infrastructure and agree that such an infrastructure can function as leverage institution between public and private institutions thus making significant contributions to the vaccine field as a whole in its quest to develop vaccines.EVRI will be launched in three phases: preparatory (during which the legal and administrative framework will be defined and a business plan will be elaborated), implementation and operational. If sufficient political and financial commitment can be secured from relevant national and European entities as well as from the private sector and other stakeholders, it could enter into operational phase from 2017 onwards. In conclusion, EVRI can make vaccine R&D more efficient and help address European and global health challenges, help alleviate the burden and spread of infectious diseases, thus contributing to the sustainability of public healthcare systems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect